Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 31, 2015 2:48 AM ET

Biotechnology

Company Overview of f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.

Company Overview

f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H., a biopharmaceutical company, designs, develops, and manufactures novel bispecific monoclonal antibodies for the treatment of serious diseases with a focus on immuno-oncology and inflammatory diseases. It offers Modular Antibody Technology, a proprietary engine that generates bispecific antibodies; Fcab, which offers a fundamentally new binding region within an antibody; mAb2 bispecific monoclonal antibodies; and IP portfolio, including patents, trademarks, and trade secrets. The company was founded in 2006 and is headquartered in Vienna, Austria. It has a research site in Cambridge, the United Kingdom.

Schwarzenbergplatz 7

Vienna,  1030

Austria

Founded in 2006

Phone:

43 72055 4215

Fax:

43 865 55 56

Key Executives for f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.

Chief Executive Officer
Chief Financial Officer
Chief Operating Officer
Managing Partner of Aescap Venture
Vice President of Development
Age: 56
Compensation as of Fiscal Year 2015.

f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Key Developments

F-star Announces Initiation of Phase 1 Clinical Trial for FS102 for the Treatment of HER2-Positive Breast and Gastric Cancer

F-star announced the initiation of a phase 1 clinical study of FS102, its lead compound for treatment of HER2-positive breast and gastric cancer. The phase 1 trial is a dose-escalating clinical study being conducted in the United States by Bristol-Myers Squibb, which acquired exclusive rights to the programme in October 2014. FS102 is a HER2-targeting antibody fragment derived from F-star's Modular Antibody TechnologyTM. In pre-clinical studies, FS102 demonstrated significant biological activity, including complete elimination of certain types of HER2 positive tumours resistant to standard-of-care due to tumour apoptosis (cell death). In addition, the company was able to identify a well-defined biomarker that has the potential to select patients that will best respond to therapy.

f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 08:30 AM

f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 08:30 AM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103, United States. Speakers: John Haurum, Chief Executive Officer.

f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 04:20 PM

f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 04:20 PM. Venue: Congress Center Basel, MCH Messe Schweiz (Basel) AG, CH-4005 Basel, Switzerland.

Similar Private Companies By Industry

Company Name Region
EccoCell Biotechnologie GmbH Europe
APEIRON Biologics AG Europe
PDC Biotech GmbH Europe
Omniofert GmbH Europe
ProtAffin Biotechnologie AG Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H., please visit www.f-star.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.